Acarbose Compared with Metformin As Initial Therapy in Patients with Newly Diagnosed Type 2 Diabetes: an Open-Label, Non-Inferiority Randomised Trial.
Wenying Yang,Jie Liu,Zhongyan Shan,Haoming Tian,Zhiguang Zhou,Qiuhe Ji,Jianping Weng,Weiping Jia,Juming Lu,Jing Liu,Yuan Xu,Zhaojun Yang,Wei Chen
DOI: https://doi.org/10.1016/s2213-8587(13)70021-4
IF: 44.867
2014-01-01
The Lancet Diabetes & Endocrinology
Abstract:Background Metformin is the only first-line oral hypoglycaemic drug for type 2 diabetes recommended by international guidelines with proven efficacy, safety, and cost-effectiveness. However, little information exists about its use in Asian populations. We aimed to ascertain the effectiveness of the a-glucosidase inhibitor acarbose, extensively adopted in China, compared with metformin as the alternative initial therapy for newly diagnosed type 2 diabetes.Methods In this 48-week, randomised, open-label, non-inferiority trial, patients who were newly diagnosed with type 2 diabetes, with a mean HbA(1c) of 7.5%, were enrolled from 11 sites in China. After a 4-week lifestyle modification run-in, patients were assigned to 24 weeks of monotherapy with metformin or acarbose as the initial treatment, followed by a 24-week therapy phase during which add-on therapy was used if prespecified glucose targets were not achieved. Primary endpoints were to establish whether acarbose was non-inferior to metformin in HbA(1c) reduction at week 24 and week 48 timepoints. The non-inferiority margin was 0.3%, with an expected null difference in the change from baseline to week 48 in HbA(1c). Analysis was done on a modified intention-to-treat population. This study was registered with Chinese Clinical Trial Registry, number ChiCTR-TRC-08000231.Findings Of the 788 patients randomly assigned to treatment groups, 784 patients started the intended study drug. HbA(1c) reduction at week 24 was -1.17% in the acarbose group and -1.19% in the metformin group. At week 48, the HbA(1c) reduction was -1.11% (acarbose) and -1.12% (metformin) with difference 0.01% (95% CI -0.12 to 0.14, p=0.8999). Six (2%) patients in the acarbose group and seven (2%) patients in the metformin group had serious adverse events, and two (1%) and four (1%) had hypoglycaemic episodes.Interpretation This study provides evidence that acarbose is similar to metformin in efficacy, and is therefore a viable choice for initial therapy in Chinese patients newly diagnosed with type 2 diabetes.